Rigel Pharmaceuticals is a profitable biotech with 127% ROE and 31% analyst upside, but revenue is down 23%, earnings quality is flagged with negative free cash flow, and earnings are expected to fall about 71% from a peak.
Thesis pillars
- High Returns Profitable Biotech→Stable
- Declining Revenue And Earnings Outlook→Stable
- Single Product Concentration↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 24, 2026, based on the 10-K filed Mar 3, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. At $50.74, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: TAVALISSE; Earnings expected to decline ~71% (cyclical peak).
Rigel Pharmaceuticals is a commercial-stage biotechnology company selling three FDA-approved products - TAVALISSE (fostamatinib) for chronic ITP, REZLIDHIA (olutasidenib) for relapsed/refractory AML with an IDH1 mutation, and GAVRETO (pralsetinib) for RET fusion-positive NSCLC... Read more
Sell if holding. At $50.74, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: TAVALISSE; Earnings expected to decline ~71% (cyclical peak). Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Score 5.6/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: speculative.
About Rigel Pharmaceuticals, Inc.
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals sold $231.9 million in combined net product revenue in 2025 across three FDA-approved medicines: TAVALISSE (fostamatinib) for chronic immune thrombocytopenia at $158.8 million, up 51.6% from 2024; GAVRETO (pralsetinib) for RET fusion-positive lung and thyroid cancers at $42.1 million, its first full year under Rigel's ownership since the June 2024 asset purchase from Blueprint Medicines; and REZLIDHIA (olutasidenib) for IDH1-mutated relapsed AML at $31.0 million.
TAVALISSE and REZLIDHIA reach patients mainly through third-party wholesale distribution, specialty pharmacy channels, and group purchasing organizations, with Rigel's sales team focused on US hematologists and hematologist-oncologists; outside the US, fostamatinib is commercialized through territorial license partners including Grifols in Europe and the UK, Kissei in Japan and Korea, Medison in Canada and Israel, and Knight in Latin America. Rigel's development pipeline centers on R289, a dual IRAK1/4 inhibitor now in Phase 1b dose-expansion for lower-risk myelodysplastic syndrome, alongside olutasidenib expansion studies run jointly with MD Anderson Cancer Center and CONNECT. A prior partnership with Eli Lilly on the RIPK1 inhibitor ocadusertib ended after Lilly terminated the collaboration effective June 15, 2026, following the earlier termination of the program's CNS-disease track in November 2025.
Show full overview
TAVALISSE faces a defined generic-entry date: Rigel settled patent litigation with Annora Pharma and Hetero in March 2025, granting a license to sell a generic version starting in the second quarter of 2032 or earlier under specified circumstances, capping the exclusivity window on the company's largest revenue product. Separately, the termination of the Lilly RIPK1 collaboration removed a partnered pipeline asset from Rigel's portfolio, leaving R289 as the most advanced wholly owned candidate still in development, with recommended Phase 2 dosing not expected until the second half of 2026.
See also: Healthcare · Biotechnology
From Rigel Pharmaceuticals, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-10-29Recent Developments — Rigel Pharmaceuticals, Inc.
Latest news
- NEWS Rigel Pharmaceuticals, Inc. Selects Onco360 Oncology Pharmacy As A National Pharmacy Partner For VEPPANU (Vepdegestrant) — marketscreener.com positive
- NEWS RIGL|Rigel Pharmaceuticals Inc|Price:37.800|Chg%:-1.270 - TradingKey — TradingKey neutral
- NEWS Rigel Pharmaceuticals Inc (RIGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey — TradingKey neutral
- NEWS RIGL|Rigel Pharmaceuticals Inc|Price:37.800|Chg%:-1.270 - tradingkey.com — tradingkey.com neutral
- NEWS Rigel Pharmaceuticals Inc (RIGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com — tradingkey.com neutral
Generated 2026-10-29T11:14:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductTAVALISSE10-K Item 1: 'In 2025, we recognized $158.8 million of TAVALISSE net product sales, a 51.6% increase compared to $104.8 million in 2024.'
Material Events(8-K, last 90d)
- 2026-07-01Item 5.02MEDIUMCMO Lisa Rojkjaer, M.D. separated from the company effective June 25, 2026; Alison Hannah, M.D. was appointed EVP and Chief Medical Officer effective July 1, 2026, resigning her board seat in connection with the appointment. Clean handoff with a named successor.SEC filing →
- 2026-05-20Item 5.02LOWStockholders approved amendments to the 2018 Equity Incentive Plan (adding 500,000 shares) and the 2000 Employee Stock Purchase Plan (adding 360,000 shares) at the May 14, 2026 Annual Meeting. Routine equity-plan approvals; no personnel change.SEC filing →
- 2026-05-20Item 5.07LOWRigel held its 2026 Annual Meeting of Stockholders on May 14, 2026, where stockholders voted on equity-plan amendments among other proposals. No adverse or contested results cited.SEC filing →
- 2026-04-21Item 1.02MEDIUMEli Lilly notified Rigel on April 16, 2026 of its election to terminate the February 2021 License and Collaboration Agreement covering ocadusertib (RIPK1 inhibitor), effective June 15, 2026; Rigel does not expect further milestones or royalties and expects to regain full rights to the compounds.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Revenue shrinking — -22.6% YoY. Growth thesis broken unless recovery story develops.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $50.74, A.R:R 0.7:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: TAVALISSE; Earnings expected to decline ~71% (cyclical peak). Chart setup: Golden cross, above all MAs, RSI 60, MACD bullish. Prior stop was $47.58. Score 5.6/10, moderate confidence.
Analyst target: $54.81 (+8.0% upside). Prior stop was $47.58. Stop-loss: $47.58.
Concentration risk — Product: TAVALISSE; Earnings expected to decline ~71% (cyclical peak); Thin upside margin: 8.0%.
Rigel Pharmaceuticals, Inc. trades at a P/E of 3.0 (forward 10.3). TrendMatrix value score: 7.7/10. Verdict: Sell.
11 analysts cover RIGL with a consensus score of 4.1/5. Average price target: $63.
What does Rigel Pharmaceuticals, Inc. do?Rigel Pharmaceuticals is a commercial-stage biotechnology company selling three FDA-approved products - TAVALISSE...
Rigel Pharmaceuticals is a commercial-stage biotechnology company selling three FDA-approved products - TAVALISSE (fostamatinib) for chronic ITP, REZLIDHIA (olutasidenib) for relapsed/refractory AML with an IDH1 mutation, and GAVRETO (pralsetinib) for RET fusion-positive NSCLC and thyroid cancer - alongside a pipeline led by the R289 IRAK1/4 inhibitor. In 2025 the company recognized $158.8 million of TAVALISSE, $31.0 million of REZLIDHIA, and $42.1 million of GAVRETO net product sales, sold through wholesale distributors and specialty pharmacies to US hematologists and oncologists.